Rhythm Biosciences Ltd. (AU:RHY)

ASX:RHY

RHY

Rhythm Biosciences Ltd.

RESEARCH TOOLSreports

Want to see AU:RHY full AI Analyst Report?

Rhythm Biosciences Ltd. (RHY) Price & Analysis

12 Followers

RHY Stock Chart & Stats

AU$0.14

<AU$0.01(1.16%)

At close: Jan 09 4:00 PM EST

AU$0.14

<AU$0.01(1.16%)

Day’s Range― - ―

52-Week RangeAU$0.05 - AU$0.28

Previous CloseN/A

Volume786.78K

Average Volume (3M)462.98K

Market Cap

AU$40.05M

Enterprise ValueAU$41.08M

Total Cash (Recent Filing)AU$1.73M

Total Debt (Recent Filing)AU$262.44K

Price to Earnings (P/E)―

Beta1.08

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding364,059,840

10 Day Avg. Volume510,821

30 Day Avg. Volume462,976

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)22.03

Price to Sales (P/S)4.56

P/FCF Ratio-4.94

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High Gross MarginA high gross margin provides structural leverage: as volumes increase the company can convert incremental revenue to gross profit more efficiently than low-margin peers. This margin cushion supports long-term unit economics for a lab/test business once scale, reimbursement and distribution are secured.

Improving Free Cash Flow TrendImproving free cash flow conversion signals progress toward cash discipline and operational tightening. Even though absolute cash flow and net income remain negative, a rising FCF trend and FCF/net income >1 indicate the business is moving toward better cash generation per loss dollar, aiding runway and funding flexibility.

Focused Diagnostic Product StrategyA clear product focus on non-invasive colorectal cancer screening targets a large, structurally growing screening market. Multiple commercialization routes (per-test sales, lab partnerships, licensing) create durable optionality: regulatory/reimbursement wins could unlock recurring per-test economics and partner distribution at scale.

Bears Say

Sharp Revenue DeclineA 42.87% year decline in revenue is a material signal of commercialization or market-adoption problems. Persistent top-line shrinkage limits the company’s ability to scale fixed-cost lab operations, delays path to positive operating leverage, and increases reliance on external funding to sustain development and go-to-market.

Persistent Negative ProfitabilityOngoing negative net, EBIT and EBITDA margins point to structural operating inefficiency or high R&D/commercial burn. Without sustained margin improvement through higher volumes or cost reduction, the company faces limited internal funding for growth and greater dilution risk from needing external capital.

Elevated Leverage And Weak Operating Cash FlowA debt-to-equity of 1.68 combined with negative operating cash flow creates refinancing and liquidity risk. Elevated leverage constrains strategic flexibility, increases fixed financing costs, and makes the company more vulnerable if commercial milestones or reimbursement outcomes are delayed.

Rhythm Biosciences Ltd. News

Rhythm Biosciences Frames ASX Position While Emphasising Limits of Investor Presentation

The latest update is out from Rhythm Biosciences Ltd. ( ($AU:RHY) ). Rhythm Biosciences has released an investor...

9d ago

RHY

Rhythm Biosciences expands ColoSTAT access program as clinician uptake grows

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has shared an update. Rhythm Biosciences has expanded its ColoSTAT Clinical Access...

18d ago

RHY

Rhythm Biosciences’ ColoSTAT Test Gains Early Clinical Traction in Underserved CRC Patients

An announcement from Rhythm Biosciences Ltd. ( ($AU:RHY) ) is now available. Rhythm Biosciences reported early clinical adoption...

1M ago

RHY

Rhythm Biosciences Schedules Investor Webinar to Update on Cancer Diagnostics Progress

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has shared an announcement. Rhythm Biosciences will host an investor webinar on...

1M ago

RHY

Rhythm Biosciences Cuts Underwritten Options Proceeds After Administrative Error

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has provided an update. Rhythm Biosciences has revised the final proceeds from...

2M ago

RHY

Rhythm Biosciences Seeks ASX Quotation for New Options

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has issued an update. Rhythm Biosciences has applied to the ASX for...

2M ago

RHY

Rhythm Biosciences Issues New Shares and Confirms Regulatory Compliance

An update from Rhythm Biosciences Ltd. ( ($AU:RHY) ) is now available. Rhythm Biosciences has issued 18,834,007 ordinary...

2M ago

RHY

Rhythm Biosciences Seeks ASX Quotation for 18.8 Million New Shares

The latest update is out from Rhythm Biosciences Ltd. ( ($AU:RHY) ). Rhythm Biosciences has applied to the...

2M ago

RHY

Rhythm Biosciences clarifies ASX query on underwriting agreement and disclosure gaps

An update from Rhythm Biosciences Ltd. ( ($AU:RHY) ) is now available. Rhythm Biosciences has responded to an...

2M ago

RHY

Rhythm Biosciences Raises $5.5m to Accelerate ColoSTAT and geneType Sales

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has issued an update. Rhythm Biosciences has completed the successful exercise and...

2M ago

RHY

RHY FAQ

What was Rhythm Biosciences Ltd.’s price range in the past 12 months?

Rhythm Biosciences Ltd. lowest share price was AU$0.05 and its highest was AU$0.28 in the past 12 months.

What is Rhythm Biosciences Ltd.’s market cap?

Rhythm Biosciences Ltd.’s market cap is AU$40.05M.

When is Rhythm Biosciences Ltd.’s upcoming earnings report date?

Rhythm Biosciences Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 75 days.

How were Rhythm Biosciences Ltd.’s earnings last quarter?

Rhythm Biosciences Ltd. released its earnings results on Feb 18, 2026. The company reported -AU$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.007.

Is Rhythm Biosciences Ltd. overvalued?

According to Wall Street analysts Rhythm Biosciences Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Rhythm Biosciences Ltd. pay dividends?

Rhythm Biosciences Ltd. does not currently pay dividends.

What is Rhythm Biosciences Ltd.’s EPS estimate?

Rhythm Biosciences Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Rhythm Biosciences Ltd. have?

Rhythm Biosciences Ltd. has 364,059,840 shares outstanding.

What happened to Rhythm Biosciences Ltd.’s price movement after its last earnings report?

Rhythm Biosciences Ltd. reported an EPS of -AU$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.381%.

Which hedge fund is a major shareholder of Rhythm Biosciences Ltd.?

Currently, no hedge funds are holding shares in AU:RHY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Rhythm Biosciences Ltd. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-476.27%

Trailing 12-Months

Asset Growth

-47.76%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Rhythm Biosciences Ltd.

Rhythm Biosciences Limited functions as a forward-thinking enterprise focused on predictive cancer diagnostics, active across both Australian and global territories. The company's core operations involve the creation, advancement, and market introduction of cutting-edge medical diagnostic technologies. A key innovation is ColoSTAT, their specialized blood test designed for the prompt and reliable identification of colorectal cancer. Established in 2017, the firm's main offices are located in Parkville, Australia.